Objective: To analyze the attitude and results of Italian epilepsy surgery centers in the surgical management of "low grade epilepsy associated neuroepithelial tumors" (LEATs). Methods: We conducted a retrospective study enrolling 339 consecutive patients with LEATs who underwent surgery between January 2009 and June 2015 at eight Italian epilepsy surgery centers. We compared demographic, clinical, pathologic, and surgical features of patients with favorable (Engel class I) and unfavorable (Engel class II, III, and IV) seizure outcome. In addition, we compared patients with tumor-associated focal cortical dysplasia (FCD) and patients with solitary tumors to identify factors correlated with FCD diagnosis. Results: Fifty-five (98.2%) of 56 patients with medically controlled epilepsy were seizure-free after surgery, compared to 249 (88.0%) of 283 patients with refractory epilepsy. At multivariate analysis, three variables independently predict unfavorable seizure outcome in the drug-resistant group. Age at surgery is largely the most significant (p = 0.001), with an odds ratio (OR) of 1.04. This means that the probability of seizure recurrence grows by 4% for every waited year. The resection site is also significant (p = 0.039), with a relative risk (RR) of 1.99 for extratemporal tumors. Finally, the completeness of tumor resection has a trend toward significance
(p = 0.092), with an RR of 1.82 for incomplete resection. Among pediatric patients, a longer duration of epilepsy was significantly associated with preoperative neuropsychological deficits (p < 0.001). A statistically significant association was observed between FCD diagnosis and the following variables: tailored surgery (p < 0.001), temporal resection (p = 0.001), and surgical center (p = 0.012). Significance: Our nationwide LEATs study gives important insights on factors predicting seizure outcome in refractory epilepsy and determining variability in FCD detection. Timely surgery, regardless of pharmacoresistance and oriented to optimize epileptologic, neuropsychological, and oncologic outcomes should be warranted. KEY WORDS: Glioneuronal tumors, Low-grade glial tumors, Focal cortical dysplasia, Seizure outcome, Neuropsychological outcome.
Low grade epilepsy associated neuroepithelial tumors (LEATs) encompass a large spectrum of low-grade glial (LGG) tumor or glioneuronal tumor (GNT) frequently encountered in epilepsy surgery practice, particularly in children and young adults. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] For this group of tumors the acronym "LEATs" (longterm epilepsy associated tumors) was proposed by Luyken et al. 1 By definition, "long term" means causing drug-resistant seizures for 2 years or more.
There is now growing consensus that some adjectives used to describe epilepsy, such as "chronic" or "long term", adopted in the past in the definition of epilepsy associated tumors, have become obsolete. 6, 7, 12, [14] [15] [16] [17] [18] Accordingly, it has been recently proposed to maintain the acronym LEATs, changing its meaning to "low grade epilepsy associated neuroepithelial tumors." 18 If uncontrolled, tumor-related epilepsy significantly affects patients' quality of life, causes cognitive deterioration, and may result in significant morbidity. 8, 17, 19 Recent reviews of literature concerning LEATs show a remarkable difficulty in establishing the preoperative drugresistance rates. 2, [9] [10] [11] 13, 20 Currently, the definition of drugresistance applies to "failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom," 21 and it may be difficult to assess this criterion in <2 years. On the other hand, assessment of drug responsiveness may necessitate at least 1 year of observation. 21 Recently the International League Against Epilepsy (ILAE) Commission on Classification and Terminology has established that a diagnosis of epilepsy can be made after a single unprovoked seizure when there is high risk for recurrence, as in presence of a structural brain lesion, including a tumor. 22 Furthermore, in the field of LEATs, where a correct histologic and molecular diagnosis is increasingly important, avoiding loss of time is essential, for epileptologic, neuropsychological, and oncologic reasons. 6, 7, 12, [14] [15] [16] [17] [18] 23 In fact, although LEATs are usually considered to have a benign indolent behavior, several reports have demonstrated that gangliogliomas (GGs) 3, 9, 13 and some glial tumors, such as pleomorphic xanthoastrocytoma (PXA), 3, 24 may exhibit an evolving course or malignant transformation.
For these reasons, an early surgical approach to LEATs may be a valuable therapeutic option, although the optimal surgical strategy, that is, lesionectomy or tailored resection, remains controversial. 1, [4] [5] [6] 12, 13, 16, 17, 25 LEATs are represented primarily by classic GNTs, that is, GGs and dysembryoplastic neuroepithelial tumors (DNETs), and are most commonly observed in a mesiotemporal location. [2] [3] [4] [5] [6] [9] [10] [11] [12] [13] 25, 26 Epileptogenic mechanisms of LEATs may be multifactorial and still not fully understood. 19 GNTs include peculiar cellular components with hyperexcitable neurons, and have neurochemical characteristics that can be relevant for epileptogenesis and intrinsic epileptogenicity. 1, 3, 26, 27 The group of LEATs is currently enlarging due to newly recognized, often rare, histotypes, such as PXA, angiocentric glioma (AG), papillary glioneuronal tumor (PGNT), extraventricular neurocytoma, 3, 24 and tumors having hybrid Key Points • Epilepsy surgery of LEATs led to a favorable seizure outcome in 88% of drug-resistant patients and in 98% of drug-responsive patients
• Younger age at surgery, temporal resection site, and complete tumor removal are predictors of a favorable seizure outcome in refractory epilepsy
• Among pediatric patients, longer duration of epilepsy is significantly associated with preoperative neuropsychological deficits
• Interobserver variability, surgical strategy (tailored resection), and anatomic site (temporal lobe) are factors related to the incidence of FCD detection
• A timely surgical treatment, oriented to optimize epileptologic, neuropsychological, and oncologic outcome should be nowadays warranted and/or mixed features (GG and DNET, PXA and GG, PXA and DNET). 3, 28 There is ongoing debate on improving consensus for histopathologic diagnosis. 18, 23, 24, 29, 30 Knowledge about molecular features of diffuse gliomas 24 and LEATs has grown rapidly. 3, 18, 23, [29] [30] [31] [32] [33] [34] LEATs show v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations in a wide percentage of cases, 3, 18, 23, [30] [31] [32] [33] [34] and mutant BRAFV600E protein in gangliogliomas is expressed predominantly by neuronal tumor cells. 32 Characterizing molecular signatures could be very helpful, allowing a more precise histologic definition and a better comprehension of both oncologic behavior 3, 14, 15, 18, 23, 29, 30, 33 and the epileptologic mechanisms involved. 35 LEATs and focal cortical dysplasia (FCD) often coexist, and the specific role of each of them in epileptogenesis is still ill-defined. 3, 5, 6, 10, 13, 16, 23, 25 However, extremely wide and hardly explicable variable percentages of association of LEATs and FCD, ranging from 0 to 80%, 3, 5, 6, 10, 13, 16, 23, 25 have been reported so far.
The main goal of this nationwide study is to analyze the attitude and results of Italian epilepsy surgery centers on the surgical treatment of LEATs to outline some controversial aspects, such as timing of surgery, surgical strategy, the factors affecting variability of FCD detection, and predictors of seizure outcome.
Materials and Methods
A retrospective multicenter cohort study enrolled 339 consecutive patients with epilepsy who underwent surgery for histopathologically confirmed LGGs and GNTs between January 2009 and June 2015 at eight Italian epilepsy surgery centers (Table 1) .
At the time of surgery, 56 patients (16.5%) were drug responsive and 283 (83.5%) were drug resistant. All operated patients underwent an individualized presurgical evaluation, which included history, careful evaluation of seizure semiology, interictal electroencephalography (EEG) and 1.5 to 3 T brain magnetic resonance imaging (MRI). In addition, long-term video-EEG monitoring and neuropsychological testing were performed as needed.
Surgical approaches were classified as either lesionectomy (removal of the structural tumoral lesion after a causal relationship with the seizure onset zone was demonstrated), or tailored resection (extended beyond tumor removal to include the surrounding epileptogenic zone, as defined by noninvasive preoperative assessment).
Seizure outcome was assessed by periodic neurologic evaluation in the outpatient setting and, in the drug-resistant group, was graded according to Engel classification. 36 Postsurgical follow-up was at least 12 months.
Furthermore, we compared patients with tumor-associated FCD with those having solitary tumors to identify possible demographic, clinical, or histopathologic factors correlated with FCD diagnosis.
Pathologic examination
All cases were histologically diagnosed according to the World Health Organization (WHO) classification of tumors of the central nervous system, 24 and the more recent classifications for FCD 37 and hippocampal sclerosis (HS).
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Whenever provided "en bloc" and "spatially oriented," the surgical specimens were submitted to a proper standardized cutting procedure using anatomic landmarks. In some cases, the neoplastic tissue was analyzed also for isocitrate dehydrogenase (IDH) and BRAF mutational status (mainly adopting mutation-specific immunohistochemistry, polymerase chain reaction [PCR] assays, or sequencing) and 1p/ 19q codeletion (by fluorescence in situ hybridization and loss of heterozygosity).
For the classification of FCD and HS, the more frequently adopted stains were represented by NeuN, microtubuleassociated protein 2 (MAP-2), phosphorylated and nonphosphorylated neurofilament protein (SMI-32), CD34, vimentin, Luxol-fast-blue, Kl€ uver-Barrera, and Nissl. In cases that are suspicious for FCD type IIIb, the areas identified as dysplastic were carefully evaluated with CD34, MAP2, p53, Ki67, and IDH1 antisera to rule out the possibility of tumor infiltration misdiagnosed as dysplastic tissue.
Statistical analysis
Three analyses were performed. The main analysis was aimed at finding predictors of seizure outcome by fitting a mixed-effects multivariate logistic regression model. The second analysis was performed to look for variables associated with FCD. Adult and pediatric populations were compared in the third analysis.
The outcome variable of the main analysis was bi-categorical: favorable outcome (Engel class I) and unfavorable outcome (Engel class II, III, and IV). A number of potentially eligible explanatory variables were considered. Four of them are numerical: age at surgery, age at seizure onset, duration of epilepsy, and number of drugs. The remaining 14 are categorical: secondary generalization, lesion remnant, resection site, type of tumor, resection side, associated FCD, gender, seizure rate, video-EEG monitoring, associated cortectomy, EEG findings, neuropsychological testing findings, drug resistance, drug therapy discontinuation. Continuous variables were described with median and interquartile range (IQR), while categorical variables with absolute and relative (%) frequency. The patient was the unit of analysis.
To select the explanatory variables to be included in the multivariate model, a preliminary advanced inspection of data was performed, including univariate analyses. Fisher's exact test was used for categorical variables and Wilcoxon rank-sum test was computed in for continuous variables. The p-values computed from such analyses were considered only in the process of variable selection. Because 34 of the analyzed patients presented with an unfavorable outcome, no more than four explanatory variables could be included simultaneously in the model. A number of preliminary models were therefore fitted, adding one by one all the eligible variables according to the p-value ascending order obtained with the univariate analysis. Only the variables that were independently significant (or at least with a trend toward significance, p-value < 0.1) were manually selected and included in the final model.
Thus, a mixed-effects logistic regression model was fitted for multivariate analysis. The epilepsy surgery center was included as a random-effect variable to control the potential confounding due to the multicenter nature of the study, and because seizure outcome was not perfectly homogenous between the several centers (p = 0.08). This model is significantly different from the one including the epilepsy surgery center as a fixed-effect variable (p = 0.02). For categorical variables, Relative risk (RR) was computed from odds ratio (OR) 39 for a better estimation of the clinical prognosis. All tests were two sided, and p < 0.05 was considered statistically significant. For variable selection, also a trend toward significance (p < 0.1) was considered sufficient for inclusion into the model. Statistical analysis was performed using software package Stata SE, 14.0.
Results
Of the 339 patients included in this study, 194 (57.2%) were male and 145 (42.8%) were female. Pediatric patients (age <18 years at surgery) were 163 (48.1%). Median age at epilepsy onset was 11 years (IQR 5-18 years), median age at surgery was 18 years (IQR 10-31 years), and median duration of epilepsy was 5 years (IQR 1.7-15 years). Tumor location was temporal in 238 patients (70.2%) and extratemporal in 101 (29.8%). The most frequent extratemporal location was frontal (30: 8.8%), followed by parietal (19: 5.6%) and occipital (3: 0.9%). In three patients (0.9%) the insula was affected and in 46 (13.6%) the tumor had multilobar extension. In 159 patients (46.9%) the lesion was on the right side and in 178 (52.5%) it was on the left. Two lesions (0.6%) presented a midline location extending to both hemispheres.
Of the 261 patients (77%) who underwent preoperative neuropsychological evaluation, 103 (39.5%) presented neuropsychological deficits.
Long-term video-EEG monitoring was performed in 238 patients (70.2%). A comparison between clinical characteristics of patients who underwent long-term video-EEG monitoring and those who did not is reported in Table 2 .
Surgical complications were reported in 19 cases (5.6%), and 26 patients (7.7%) exhibited postoperative neurologic deficits. Fifteen patients (4.4%) presented sensorimotor deficits, eight patients (2.4%) aphasia, and three patients (0.9%) unexpected visual field defects.
Histologic examination of surgical specimens revealed 250 glioneuronal tumors (73.7%), 87 glial tumors (25.7%), and two mixed forms (0.6%). Tumor-associated FCD was diagnosed in 60 patients (17.7%). FCD type IIIb was present in 44 cases (13%), whereas FCD type IIa was present in 8 patients (2.4%) and FCD not otherwise specified in eight (2.4%) (histologic types and their association with FCD are reported in Table 3 ). Seven patients (2.1%) had HS. Among tumor markers, the most frequently tested was CD34 (162: 47.8%), followed by IDH1 mutation (68: 20.1%), 1p/19q codeletion (31: 9.1%), and BRAF mutation (28: 8.3%). Tumor marker analysis was different across centers.
Additional data are summarized in Table 4 . At follow-up, complete seizure control was achieved in 304(89.7%) of 339 patients. In 298 of 339 patients, data on postoperative antiepileptic drug (AED) intake were available. Among them, 122 patients (40.9%) were able to discontinue anticonvulsant therapy after surgery.
Two hundred forty-nine of the 283 drug-resistant patients (88.0%) were seizure-free after surgery; in 93 (38.1%) of them, AEDs were discontinued (39 missing data). Most patients with refractory epilepsy were adults (158, 55.8%). Surgical complications were reported in 16 patients (5.7%).
Fifty-five of the 56 drug-responsive patients (98.2%) were seizure-free after surgery, in 29 (53.7%) of them, AEDs were discontinued (two missing data). Most patients with drug-responsive epilepsy were children (38, 67.9%). Surgical complications were reported in three patients (5.4%).
Main analysis-Predictors of seizure outcome
Fifty-six of 339 patients were not drug-resistant at the time of surgery and were therefore excluded from statistical analyses. One additional patient was excluded for the incompleteness of data. Thus data from 282 patients were analyzed. Three variables (EEG, neuropsychological findings, and drug-therapy discontinuation) were not included in the analysis due to the high number of missing data.
Two hundred forty-eight (87.9%) of the 282 patients included in the analysis presented with a favorable outcome. We did not consider follow-up duration in the analysis of outcome due to the relatively homogeneous length of follow-up between patients (median 3 years, IQR 1-5 years).
Analyzed data and the results of the preliminary univariate analysis are reported in Table 5 .
The results of multivariate analysis are reported in Table 6 . Lower age at surgery and temporal resection site are independent positive predictors of seizure outcome. In addition, the absence of a postoperative tumor remnant independently predicts a favorable seizure outcome, although with only a trend toward significance.
Second analysis-Factors associated with FCD
Univariate analysis demonstrated four significant factors associated with FCD detection: tailored surgery (p < 0.001), temporal resection (p = 0.001), tumor type (p = 0.008), and the surgical center (p = 0.012). The following variables did not show a significant association with FCD: age at epilepsy onset (p = 0.490), age at surgery (p = 0.511) duration of epilepsy (p = 0.725), gender (p = 0.250), secondary generalization (p = 0.595), and seizure frequency (p = 0.914).
Third analysis-Comparison between adult and pediatric patients
No significant association was found between seizure outcome and presurgical, surgical, or postsurgical features when the adult and pediatric populations were analyzed separately.
Among pediatric patients, a longer duration of epilepsy was significantly associated with preoperative neuropsychological deficits (p < 0.001). The median duration of epilepsy was 2 years (IQR 0.8-3 years) in patients with normal neuropsychological evaluation and 4 years (IQR 3-8 years) in those with neuropsychological deficits. Among adult patients, no significant association was demonstrated between duration of epilepsy and preoperative neuropsychological deficits (p = 0.112). The median (Fig. 1) .
Discussion
Although data on LEATs have extensively been reported in the literature, studies on large series remain rare 2, 4, [9] [10] [11] [12] [13] and focused mainly on clinical and survival aspects rather than on epilepsy. 40 Our nationwide retrospective study enrolled 339 patients, including both adults and children.
It is well known that LEATs are extremely responsive to surgical treatment, with 70-90% of patients achieving seizure freedom after surgery. 2, [4] [5] [6] [7] [9] [10] [11] [12] [13] In line with literature data, complete seizure control was achieved in 89.7% of patients. In the drug-responsive group, 98.2% of patients were seizure-free after surgery, compared to 88.0% of the refractory group. Furthermore, 122 patients (40.9%) discontinued AEDs after surgery (41 missing data): 29 (53.7%) in the drug-responsive group and 93 (38.1%) in the refractory group.
Patients included in this study had a minimum follow-up of 12 months, which we deemed as the minimum duration allowing for proper assessment of outcome, based on studies showing that the highest rate of seizure recurrence after surgery for LEATs occurred within the first year. 11, 12 Among the three variables that independently predict seizure outcome at multivariate analysis, age at surgery is largely the most significant, and the probability of unfavorable outcome grows by 4% for every waited year. This finding is in agreement with those of a previous study. 12 As previously reported, 17 our findings corroborate the relationship between longer duration of epilepsy and development of neuropsychological deficits in pediatric patients. The median duration of epilepsy was significantly shorter among our pediatric patients, with normal preoperative neuropsychological findings compared to those with neuropsychological deficits (2 vs. 4 years).
We therefore suggest that surgery in these patients should be considered as an early option, even before drug resistance is formally assessed, to limit the risk for cognitive deterioration secondary to ongoing seizures and administration of multiple AEDs , as well as to achieve a correct histologic and molecular diagnosis, which is increasingly important for oncologic management. 18, 23 In support of this policy, our data show a high rate of postoperative seizure control (98.2%) in drug-responsive patients, with more than half of them then discontinuing AEDs, which outweighs the relatively small risks of surgery.
It is well known that in patients with tumor-associated epilepsy the extent of tumor resection correlates with improved survival, as well as with the chances of postoperative seizure control. 2, 4, [8] [9] [10] 12, 13, 17 In our series, the association between seizure recurrence and the presence of a postoperative tumor remnant shows a trend toward significance, and the probability of unfavorable outcome is almost twofold when the tumor resection is incomplete.
In our study, FCD was present in 18.3% and HS in 2.3% of surgical specimens. The association of LEATs with other epileptogenic structural abnormalities, including the spectrum of FCDs 6,7,16,25,37 or rarely HS, 5,6,38 may underlie a widespread epileptogenic network. FCD associated with LEATs is usually represented by FCD type I and, according to the ILAE classification, 37 is diagnosed as FCD type IIIb. Preoperative identification of FCD type I may be challenging, as it is usually more difficult to identify on MRI. 6, 16, 25, 37, 41 Percentages of tumor-associated FCD varied significantly across participating centers, ranging from 0 to 27% in adults, and 0 to 50% in children, confirming the previously reported variability. 3, 6, 10, 13, 23, 25 There may be several reasons for this variability. 18, 23 Classification of the different types of FCD can be challenging; therefore, a first explanation might be related to objective difficulties in classifying some specimens and to interobserver variability. 18 ,23,30,37 Another confounding factor might be related to the type of surgical strategy, that is, lesionectomy or tailored resection, and therefore the availability of an adequate surgical specimen for histopathologic examination. 25, 30 In fact, we found a statistically significant association between FCD and tailored surgery as well as temporal location.
In our series, patients with tumor alone or with a tumorassociated FCD had similar postoperative seizure outcomes, as reported previously. 25 A similar finding was obtained by evaluating subsets of patients, including those with a diagnosis of GG, DNET, and PXA. This finding might be influenced by the wide variability observed in reporting FCD and in the different surgical strategies adopted across participating centers.
Consistent with these possible explanations, in our study we found a statistically significant association between cooccurring FCD and surgical strategy (p < 0.001).
However, the specific role of the associated pathologies in epileptogenesis and their clinical relevance are still unclear, 1, [5] [6] [7] 18, 23, 25, 29, 37 and represent a complex topic deserving further investigation. 3, 18, 23, 29 Our findings confirm the predilection of LEATs for the temporal lobe, 2, [4] [5] [6] [7] 11, 12 across all ages (adults 77.7%, children 62%). The resection site showed a significant association with seizure outcome and the probability of unfavorable outcome was twofold when the tumor was extratemporal. These findings are in line with those of previous studies. 7, 9, 12, 20 The best surgical strategy in patients with tumoral epilepsy, particularly in the temporal lobe, remains poorly defined and is still a matter of discussion, with surgical strategies varying from simple lesionectomy 4, 5, 7, 12, 16, 26, 42 to more extensive resections. [4] [5] [6] [7] 16, 25, 26 Moreover, heterogenous terminology (anterior temporal lobectomy, anteromesial temporal lobectomy, lesionectomy with corticectomy, lesionectomy with amygdala-hippocampectomy, extended lesionectomy, tailored lesionectomy, and so on) 4, 6, 9, 10, 12, 13, 16 makes comparisons even more difficult. Therefore, we have defined the resection of the tumor alone as lesionectomy and the removal of tumor and surrounding epileptogenic zone as tailored resection.
In the present series, lesionectomy was performed mainly in extratemporal tumor locations (64.1% in adults and 85.5% in children), as reported previously. [5] [6] [7] 9, 16, 25 Conversely, tailored surgery prevailed in temporal lobe resections (84.7% in adults and 50.5% in children).
Furthermore, surgical strategy was influenced by the use of different surgical procedures in different centers, with three favoring lesionectomy (two of them being pediatric centers) and two other preferring tailored surgery. However, in our series, as in another recent report, 12 the univariate analysis showed no significant association between surgical strategy and seizure outcome (p = 1).
It has been suggested that both the frequent localization of LEATs in the temporal lobe, particularly mesially (the uncus-amygdala-entorhinal zone, sometimes involving the hippocampal head) and the possible coexistence of FCD in the adjacent temporopolar cortex, may influence how extended the epileptogenic zone is. [5] [6] [7] 23, 29 These LEATspecific features can legitimate a "tailored" surgical approach extending beyond tumor removal, with additional hippocampectomy and/or temporal pole corticectomy. 1, [4] [5] [6] [7] 11, 12, 16, 23, 25, 29 In most of our patients, the extension of the epileptogenic zone (the minimum cortical area that should be removed or disconnected to render the patient seizure-free 41 ) and the choice of the best surgical strategy (lesionectomy or tailored resection) were assessed preoperatively noninvasively, with particular attention to lesion site/size, ictal semiology, and EEG findings. No intraoperative tool (e.g., electrocorticography, ECoG) was employed to determine the extent of Output of the fitted mixed-effect logistic regression model. The center was considered as a random-effect variable. This model is significantly different from the one including the center as a fixed-effect variable (p = 0.02).
Coeff, Coefficient; SE, standard Error; OR, odds ratio; CI, confidence interval; RR, relative risk; Extra-T, extratemporal.
Figure 1.
Median duration of epilepsy in patients with normal neuropsychological evaluation and neuropsychological deficits: comparison of adult and pediatric patients. Epilepsia ILAE removal of the epileptogenic tissue. As a matter of fact, the usefulness of ECoG is still controversial. [8] [9] [10] 20 Outcome was equally good for patients who underwent video-EEG and those who did not. This is an important finding, suggesting that when a lesion as obvious as a LEAT is detected and is concordant with seizure semiology and interictal EEG, the costs and potential risks of long-term monitoring (often requiring AEDs withdrawal) may be avoided.
Knowledge about molecular features of LEATs is rapidly growing. 3, 18, 23, 24, [29] [30] [31] [32] [33] [34] Our findings showed that biomarkers, including BRAF, 1p19q, IDH1, and CD34, were systematically used only by few centers.
Molecular testing for these tumors should be encouraged, because it may result in more detailed histologic diagnosis and oncologic prognostication, as well as in the understanding of epileptogenic mechanisms and personalized therapeutic strategies.
Although our study has limitations due to its retrospective nature, it also has strengths in relation to the nationwide approach, allowing a large series being recruited in a relatively short time. The fundamental aim of this study was to evaluate seizure outcome; therefore, we did not analyze data on postoperative neuropsychological status-we suggest that a thorough discussion of this essential topic may be a matter for future studies.
Findings, such as the variability of associated FCD detection and lack of a homogeneous terminology for surgical techniques should also be addressed by subsequent studies and consensus reports, respectively.
Conclusions
Our nationwide study suggests that early surgical treatment of LEATs, irrespective of the preoperative responsiveness to drugs, may highly contribute to seizure control and reduce the risk of associated neuropsychological deficits. In the drug-responsive group, 98.2% of patients were seizurefree after surgery, compared to 88.0% of patients with refractory epilepsy. In the setting of drug-resistant epilepsy we found that younger age at surgery, temporal location, and complete tumor resection were predictors of favorable seizure outcome. Another important finding of our study is that the rate of FCD detection is influenced by the surgical strategy adopted (tailored resection) and the anatomic site (temporal lobe), as well as by the objective diagnostic challenges and consequent interobserver variability among surgical centers.
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